Clearity’s Perspective: If you or someone you love has been diagnosed with low-grade serous ovarian cancer (LGSOC), consider registering to attend Clearity’s live webinar, “But This Is Different: Understanding and Getting Support for the Unique Needs of People with Low-Grade … Read more
by Lauren Comander
Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., are taking on the world of ovarian cancer research. As researchers for Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the duo is
… Read moreby Chris Ryan
TORL-1-23, a Claudin-6 (CLDN6)–targeted antibody-drug conjugate (ADC), led to responses in patients with heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer. Additionally, the agent was well tolerated, according to data from the phase 1 TORL-123-001 … Read more
by Rose McNulty
Mirvetuximab soravtansine showed promise for patients with heavily pretreated FRα-positive, platinum-sensitive ovarian cancer—a challenging patient population to treat—in the phase 2 PICCOLO trial. New data from the study presented at the European Society for Medical Oncology (ESMO) … Read more
by Jason M. Broderick
The TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) showed promising antitumor activity with manageable toxicity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy, according to results from the phase 2 TROPION-PanTumor03 … Read more
At the ESMO Congress 2024 (Barcelona, 13–17 September), final overall survival (OS) data after a median follow-up of approximately 6 years revealed no benefit of niraparib maintenance over placebo for patients newly diagnosed with advanced ovarian cancer at high risk … Read more
by University of Birmingham
A study published in the International Journal of Gynecological Cancer found that the UK’s protocol for picking up early-stage disease in women with high grade serous ovarian cancer—the most common, aggressive, and lethal form of the … Read more
As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more
by Wayne Kuznar
CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more
by Silas Inman
The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more
by Ariana Pelosci
Results of a recent study published in the Journal of Clinical Oncology highlighted the association of ovarian cancer with talcum powder (talc) use.1 The findings were from an extensive analysis of the Sister Study cohort.… Read more
Clearity offers emotional support to individuals with ovarian cancer through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors may be … Read more
by Cynthia McCormick Hibbert
For too many cancer survivors, life after treatment is fraught with a decline in cognitive function known as “chemo brain.”
A newly published study by a Northeastern professor says that yoga might hold the key to … Read more
by Sabrina Serani
The FDA announced new guidance to expand eligibility criteria with the goal of improving participation and diversity in oncology clinical trials.These 3 areas of change include laboratory values, washout periods, and performance status.
While the FDA notes … Read more
By Ryan Scott
Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more
By Kristi Rosa
Rezatapopt (PC14586) elicited responses with a favorable toxicity profile in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations, according to data from the phase 1/2 PYNNACLE study (NCT04585750) presented at the 2024 SGO Annual … Read more
By Mark Fuerst
About half of patients with platinum-sensitive relapsed ovarian cancer (PSROC) on maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) therapy who showed RECIST progression did not have cancer antigen-125 (CA-125) progression, challenging current guidelines, according to a new study.… Read more
— “If the patients are not taking the drug, then it’s not going to work”
By Associated Press.
For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary.
They’ve ignited a movement to radically change … Read more
Clearity offers emotional support to people diagnosed with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personalized, one-to-one assistance with navigating the impact of an ovarian cancer diagnosis, our team of OC Counselors … Read more
By Ashley Chan
A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.
A phase 3 trial analyzing the treatment combination of avutometinib and defactinib compared with … Read more
